Safety and preliminary efficacy from the phase 1 portion of MasterKey-01: A First-in-human dose-escalation study to determine the recommended phase 2 dose (RP2D), pharmacokinetics (PK) and preliminary antitumor activity of BDTX-189, an inhibitor of allosteric ErbB mutations, in patients (pts) with advanced solid malignancies.

Title

Safety and preliminary efficacy from the phase 1 portion of MasterKey-01: A First-in-human dose-escalation study to determine the recommended phase 2 dose (RP2D), pharmacokinetics (PK) and preliminary antitumor activity of BDTX-189, an inhibitor of allosteric ErbB mutations, in patients (pts) with advanced solid malignancies.

Authors

Keywords

-

Journal

JOURNAL OF CLINICAL ONCOLOGY

Volume 39, Issue 15_suppl, Pages 3086-3086

Publisher

American Society of Clinical Oncology (ASCO)

Online

2021-06-02

DOI

10.1200/jco.2021.39.15_suppl.3086